Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis

Study Identifier
M02-516
CT.gov Identifier
NCT00062699
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Other
Sign up for trial alerts

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Kidney Disease
    • Study Drug
  • Zemplar (paricalcitol injection)
  • Calcijex
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    20+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    Stage V Chronic Kidney Disease Patients on Hemodialysis requiring treatment for secondary hyperparathyroidism with vitamin D therapy

    Protocol Summary

    To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for

    the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney

    disease on hemodialysis as measured by time to death.

    Study Locations

    Location
    Status
    Location
    Joslin Diabetes Center
    Boston, Massachusetts, United States, 02215
    16.0 miles (25.6 km) away from your location
    Status
    Not applicable